NCT05906524 2024-01-10
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
Shanghai Kanda Biotechnology Co., Ltd.
Phase 1/2 Unknown
Clinical Trials
4 trialsNCT05840835 2023-08-08
IMMINENT-01
Immix Biopharma, Inc.
Phase 1/2 Unknown
NCT05833984 2023-04-27
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2 Unknown
NCT05441046 2022-07-06
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Unknown